The evaluation of liver fibrosis by acoustic radiation force impulse (ARFI) in hemodialysis patients with chronic hepatitis C

The evaluation of liver fibrosis by acoustic radiation force impulse (ARFI) in hemodialysis patients with chronic hepatitis C - The accuracy of ARFI in assessing liver fibrosis of hemodialysis patients with chronic hepatitis C

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000011248

Enrollment

160

Registered

2013-08-01

Start date

2013-06-19

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Hemodialysis patients with chronic hepatitis C (HCV antibody positive, HCV-RNA positive) - Non-hemodialysis patients with chronic hepatitis C (HCV antibody positive, HCV-RNA positive) - Hemodialysis patients without HCV (HCV antibody negative)

Exclusion criteria

Exclusion criteria: 1) Patients under 20 years old 2) Patients with co-infection with hepatitis B virus 3) Patients with co-infection with human immunodeficiency virus 4) Patients with alcoholic liver disorder or autoimmune hepatitis 5) Patients with uncompensated cirrhosis or hepatic failure 6) Patients with multiple organ failure or immunological deficiency 7) Patients with severe depression or past history of psychiatric disorder 8) Patients in pregnancy or lactating or patients who expect to become pregnant 9) Patients whose hemoglobin levels are less than 8.5g/dL 10) Patients whose platelet counts are less than 25,000/microL 11) Patients whose neutrophil counts are less than 500 /microL 12) Patients whom investigator disqualified

Design outcomes

Primary

Measure	Time frame
- The accuracy of ARFI for evaluation of liver fibrosis in hemodialysis patients with chronic hepatitis C - Comparison of the degree of liver fibrosis between hemodialysis patients with CH-C, non-hemodialysis patients with CH-C and hemodialysis patients without HCV infection - Comparison for progression rate of fibrosis by ARFI between CH-C patients with or without hemodialysis - Comparison for cumulative incidence of HCC by ARFI between CH-C patients with or without hemodialysis - Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Peg-IFN alpha mono-therapy in CH-C patients with hemodialysis - Comparison of regression rate of liver fibrosis and suppressive effect on HCC incidence of Peg-IFN alpha mono-therapy in CH-C patients with hemodialysis between CH-C patients with or without HD and HD patients without HCV infection	—

Measure

Time frame

- The accuracy of ARFI for evaluation of liver fibrosis in hemodialysis patients with chronic hepatitis C - Comparison of the degree of liver fibrosis between hemodialysis patients with CH-C, non-hemodialysis patients with CH-C and hemodialysis patients without HCV infection - Comparison for progression rate of fibrosis by ARFI between CH-C patients with or without hemodialysis - Comparison for cumulative incidence of HCC by ARFI between CH-C patients with or without hemodialysis - Investigating sustained virological response rate (the rate of undetectable HCV RNA at end of treatment and at 24 weeks after completion of treatment) of Peg-IFN alpha mono-therapy in CH-C patients with hemodialysis - Comparison of regression rate of liver fibrosis and suppressive effect on HCC incidence of Peg-IFN alpha mono-therapy in CH-C patients with hemodialysis between CH-C patients with or without HD and HD patients without HCV infection

—

Countries

Japan

Contacts

Public ContactYuki Tahata

2-2 Yamadaoka Suita Osaka Japan Gastroenterology and Hepatology

yuki.tahata@gh.med.osaka-u.ac.jp06-6879-5111

Outcome results